We are live on ! Find out more
HP

HealthInvest Partners Portfolio holdings

AUM $372M
1-Year Est. Return 59.89%
This Fund
S&P 500
This Quarter Est. Return
-5.06%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$109M
AUM Growth
-$25.8M
Cap. Flow
-$18.5M
Cap. Flow %
-17.03%
Top 10 Hldgs %
81.1%
Holding
19
New
4
Increased
1
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$8.4M
2
MCK icon
McKesson
MCK
+$8.38M
3
ELOS
Syneron Medical Ltd
ELOS
+$5.53M
4
SUPN icon
Supernus Pharmaceuticals
SUPN
+$3.55M
5
ATEC icon
Alphatec Holdings
ATEC
+$2.31M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$10.7M
2
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$9.94M
3
COR icon
Cencora
COR
+$8.19M
4
CAH icon
Cardinal Health
CAH
+$8.17M
5
PGNX
Progenics Pharmaceuticals Inc
PGNX
+$1.77M

Sector Composition

Rank Sector Weight
1 Healthcare 83.29%
2 Financials 6.95%
3 Industrials 4.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SUPN icon
1
Supernus Pharmaceuticals
SUPN
$2.59B
$13.6M 12.52%
538,241
+158,708
+42% +$3.55M
ANIK icon
2
Anika Therapeutics
ANIK
$258M
$8.62M 7.94%
175,967
-27,526
-14% -$1.27M
CAH icon
3
Cardinal Health
CAH
$53.9B
$8.48M 7.81%
117,800
-113,000
-49% -$8.17M
CRL icon
4
Charles River Laboratories
CRL
$11.2B
$8.47M 7.8%
111,112
-7,500
-6% -$570K
COR icon
5
Cencora
COR
$60.6B
$8.37M 7.71%
107,000
-105,000
-50% -$8.19M
TARO
6
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$8.31M 7.65%
78,905
-6,300
-7% -$660K
ELV icon
7
Elevance Health
ELV
$81.5B
$8.09M 7.46%
56,300
-79,600
-59% -$10.7M
GILD icon
8
Gilead Sciences
GILD
$162B
$8.09M 7.46%
+113,000
New +$8.4M
MRK icon
9
Merck
MRK
$322B
$8.01M 7.38%
142,633
-22,008
-13% -$1.29M
MCK icon
10
McKesson
MCK
$100B
$8.01M 7.38%
+57,000
New +$8.38M
GTS
11
DELISTED
Triple-S Management Corporation
GTS
$7.54M 6.95%
382,767
-69,108
-15% -$1.44M
ELOS
12
DELISTED
Syneron Medical Ltd
ELOS
$5.93M 5.46%
+706,107
New +$5.53M
GNC
13
DELISTED
GNC Holdings, Inc.
GNC
$4.67M 4.3%
422,955
-60,000
-12% -$939K
ATEC icon
14
Alphatec Holdings
ATEC
$1.46B
$1.37M 1.26%
+426,855
New +$2.31M
ICCC icon
15
ImmuCell
ICCC
$101M
$1M 0.92%
168,323
– –
BIL icon
16
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$47.1B
– –
-10,000
Closed -$915K
SHY icon
17
iShares 1-3 Year Treasury Bond ETF
SHY
$25.5B
– –
-10,000
Closed -$850K
SYNH
18
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
– –
-222,875
Closed -$9.94M
PGNX
19
DELISTED
Progenics Pharmaceuticals Inc
PGNX
– –
-280,000
Closed -$1.77M

Similar funds

KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
AWA
Acumen Wealth Advisors Chattanooga, Tennessee $372M AUM
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
PAA
Peregrine Asset Advisers Portland, Oregon $371M AUM 41.36% 1-Year Est. Return
PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return

HealthInvest Partners's Q4 2016 Portfolio in Review

As of Q4 2016, HealthInvest Partners held 19 positions worth $109M, down 19% from $134M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

HealthInvest Partners withdrew a net $18.5M in Q4 2016, closing 4 positions and reducing 9 holdings. Its most notable exit was Syneos Health, Inc. Class A Common Stock, an estimated $9.94M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 84% a quarter earlier, followed by Financials and Industrials.

Against the trend, HealthInvest Partners opened a new position in Gilead Sciences worth $8.09M.

  • HealthInvest Partners's largest Q4 2016 buy was Gilead Sciences: 113,000 shares worth $8.09M.
  • HealthInvest Partners added most to Supernus Pharmaceuticals in Q4 2016, an estimated $3.55M increase.
  • HealthInvest Partners's biggest Q4 2016 reduction was Elevance Health, cutting an estimated $10.7M.
  • HealthInvest Partners fully exited Syneos Health, Inc. Class A Common Stock in Q4 2016, selling an estimated $9.94M.
  • HealthInvest Partners's ten largest holdings make up 81% of its $109M portfolio in Q4 2016.
  • HealthInvest Partners opened 4 new positions and closed 4 in Q4 2016.
  • HealthInvest Partners's portfolio value fell 19% quarter-over-quarter to $109M.

Based on HealthInvest Partners's 13F filing for Q4 2016, filed 24 Jan 2017.